Tesamorelin / Ipamorelin
≥99% HPLC verified · 2 sizes available
Synergistic blend of stabilized GHRH analog and GHS-receptor agonist for paired endocrine pathway research.
Size
What research has shown
Synthetic compound
Defined synthetic material for controlled laboratory research and analytical method development.
In the literature
Cited across published research on peptide stability, receptor interaction, and biological signaling.
Lab settings
Examined in vitro and in preclinical models. Studies focus on molecular properties under controlled systems.
Non-therapeutic
For laboratory research only. Not approved for human consumption, treatment, or therapeutic application.
About this compound
A pre-blended formulation of Tesamorelin (10mg) and Ipamorelin (3mg). The blend is referenced in research literature on combined long-acting GHRH-receptor signaling and selective GHS-receptor pathway signaling, allowing parallel investigation of both pathways in a single reconstitution.
Each lot is independently HPLC-verified for both component peptides separately, with a combined Certificate of Analysis documenting each peptide's identity, purity, and concentration.
This material is supplied for in vitro research only. It is not a drug, supplement, food, or cosmetic, and is not for human or veterinary consumption.
This material is supplied for in vitro research only. It is not a drug, supplement, food, or cosmetic, and is not for human or veterinary consumption.
Specifications
| Form | Lyophilized powder (combined) |
| Purity | ≥99% |
| Size | 3MG |
| Vial | 3ML |
| Storage | -20°C, desiccated, protected from light |
| Origin | USA |
Reconstitution, storage, and handling are the responsibility of the qualified researcher.Perplexa Labs does not provide protocols, dosing guidance, or human-use instructions.